This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (286)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Men's Health  • Prostate Disease  • Oncology  • Prostate Cancer  • Prognosis/ Outcomes  • Alert me on articles by topic  Social Bookmarking   What's this?

Peter C. Albertsen, MD, MS; James A. Hanley, PhD; Judith Fine, BA

JAMA. 2005;293:2095-2101.

Context  The appropriate therapy for men with clinically localized prostate cancer is uncertain. A recent study suggested an increasing prostate cancer mortality rate for men who are alive more than 15 years following diagnosis.

Objective  To estimate 20-year survival based on a competing risk analysis of men who were diagnosed with clinically localized prostate cancer and treated with observation or androgen withdrawal therapy alone, stratified by age at diagnosis and histological findings.

Design, Setting, and Patients  A retrospective population-based cohort study using Connecticut Tumor Registry data supplemented by hospital record and histology review of 767 men aged 55 to 74 years with clinically localized prostate cancer diagnosed between January 1, 1971, and December 31, 1984. Patients were treated with either observation or immediate or delayed androgen withdrawal therapy, with a median observation of 24 years.

Main Outcome Measures  Probability of mortality from prostate cancer or other competing medical conditions, given a patient’s age at diagnosis and tumor grade.

Results  The prostate cancer mortality rate was 33 per 1000 person-years during the first 15 years of follow-up (95% confidence interval [CI], 28-38) and 18 per 1000 person-years after 15 years of follow-up (95% CI, 10-29). The mortality rates for these 2 follow-up periods were not statistically different, after adjusting for differences in tumor histology (rate ratio, 1.1; 95% CI, 0.6-1.9). Men with low-grade prostate cancers have a minimal risk of dying from prostate cancer during 20 years of follow-up (Gleason score of 2-4, 6 deaths per 1000 person-years; 95% CI, 2-11). Men with high-grade prostate cancers have a high probability of dying from prostate cancer within 10 years of diagnosis (Gleason score of 8-10, 121 deaths per 1000 person-years; 95% CI, 90-156). Men with Gleason score of 5 or 6 tumors have an intermediate risk of prostate cancer death.

Conclusion  The annual mortality rate from prostate cancer appears to remain stable after 15 years from diagnosis, which does not support aggressive treatment for localized low-grade prostate cancer.

Author Affiliations: Division of Urology, University of Connecticut Health Center, Farmington (Dr Albertsen and Ms Fine); and Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec (Dr Hanley).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Localized Prostate Cancer and DNA Ploidy
Leopold G. Koss
JAMA. 2005;294(10):1207.
EXTRACT | FULL TEXT  

Localized Prostate Cancer and DNA Ploidy—Reply
Peter C. Albertsen, James A. Hanley, and Judith Fine
JAMA. 2005;294(10):1207-1208.
EXTRACT | FULL TEXT  

RELATED ARTICLE

The Natural History of Clinically Localized Prostate Cancer
Peter H. Gann and Misop Han
JAMA. 2005;293(17):2149-2151.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prospective Study of Prostate Tumor Angiogenesis and Cancer-Specific Mortality in the Health Professionals Follow-Up Study
Mucci et al.
JCO 2009;27:5627-5633.
ABSTRACT | FULL TEXT  

Macrophage Inhibitory Cytokine 1: A New Prognostic Marker in Prostate Cancer
Brown et al.
Clin. Cancer Res. 2009;15:6658-6664.
ABSTRACT | FULL TEXT  

An Iatrogenic Confounding Variable
Albertsen
JNCI J Natl Cancer Inst 2009;101:1368-1369.
FULL TEXT  

Detection of Aggressive Primary Prostate Cancer with 11C-Choline PET/CT Using Multimodality Fusion Techniques
Piert et al.
JNM 2009;50:1585-1593.
ABSTRACT | FULL TEXT  

The Effect of a Novel Botanical Agent TBS-101 on Invasive Prostate Cancer in Animal Models
EVANS et al.
Anticancer Res 2009;29:3917-3924.
ABSTRACT | FULL TEXT  

Screening for prostate cancer remains controversial
Stark et al.
BMJ 2009;339:b3601-b3601.
FULL TEXT  

Outcomes of Localized Prostate Cancer Following Conservative Management
Lu-Yao et al.
JAMA 2009;302:1202-1209.
ABSTRACT | FULL TEXT  

Dysfunctional Transforming Growth Factor-{beta} Receptor II Accelerates Prostate Tumorigenesis in the TRAMP Mouse Model
Pu et al.
Cancer Res. 2009;69:7366-7374.
ABSTRACT | FULL TEXT  

Prostate Cancer-Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era
Stephenson et al.
JCO 2009;27:4300-4305.
ABSTRACT | FULL TEXT  

Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy
Cooperberg et al.
JCO 2009;27:4306-4313.
ABSTRACT | FULL TEXT  

A 72-Year-Old Man With Localized Prostate Cancer--14 Years Later
Delbanco and Albertsen
JAMA 2009;302:1105-1106.
FULL TEXT  

MicroRNA Regulation of Oncolytic Herpes Simplex Virus-1 for Selective Killing of Prostate Cancer Cells
Lee et al.
Clin. Cancer Res. 2009;15:5126-5135.
ABSTRACT | FULL TEXT  

Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis
Cooperberg et al.
JNCI J Natl Cancer Inst 2009;101:878-887.
ABSTRACT | FULL TEXT  

Molecular Markers and Death From Prostate Cancer
Concato et al.
ANN INTERN MED 2009;150:595-603.
ABSTRACT | FULL TEXT  

Patients' Survival Expectations before Localized Prostate Cancer Treatment by Treatment Status
Mohan et al.
J Am Board Fam Med 2009;22:247-256.
ABSTRACT | FULL TEXT  

Evaluation of 8q24 and 17q Risk Loci and Prostate Cancer Mortality
Penney et al.
Clin. Cancer Res. 2009;15:3223-3230.
ABSTRACT | FULL TEXT  

Identification of a Biphasic Role for Genistein in the Regulation of Prostate Cancer Growth and Metastasis
El Touny and Banerjee
Cancer Res. 2009;69:3695-3703.
ABSTRACT | FULL TEXT  

Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer
Migita et al.
JNCI J Natl Cancer Inst 2009;101:519-532.
ABSTRACT | FULL TEXT  

Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole et al.
NEJM 2009;360:1310-1319.
ABSTRACT | FULL TEXT  

In vivo Knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors
Snoek et al.
Clin. Cancer Res. 2009;15:39-47.
ABSTRACT | FULL TEXT  

Management of Prostate Cancer
NEJM 2008;359:2605-2609.
FULL TEXT  

Effect of a Dementia Diagnosis on Survival of Older Patients After a Diagnosis of Breast, Colon, or Prostate Cancer: Implications for Cancer Care
Raji et al.
Arch Intern Med 2008;168:2033-2040.
ABSTRACT | FULL TEXT  

Cancer Risk Assessment and Cancer Prevention: Promises and Challenges
Reid
Cancer Prevention Research 2008;1:229-232.
FULL TEXT  

Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force
Lin et al.
ANN INTERN MED 2008;149:192-199.
ABSTRACT | FULL TEXT  

Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort
Mucci et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:1682-1688.
ABSTRACT | FULL TEXT  

Vitamin D and Prostate Cancer Risk--A Less Sunny Outlook?
Mucci and Spiegelman
JNCI J Natl Cancer Inst 2008;100:759-761.
FULL TEXT  

Case 15-2008 -- A 55-Year-Old Man with an Elevated Prostate-Specific Antigen Level and Early-Stage Prostate Cancer
Barry et al.
NEJM 2008;358:2161-2168.
FULL TEXT  

Profile-specific survival estimates: Making reports of clinical trials more patient-relevant
Julien and Hanley
Clin Trials 2008;5:107-115.
ABSTRACT  

Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer
Wilt et al.
ANN INTERN MED 2008;148:435-448.
ABSTRACT | FULL TEXT  

Complexities of Prostate-Cancer Risk
Gelmann
NEJM 2008;358:961-963.
FULL TEXT  

Baseline Prostate-Specific Antigen Level and Risk of Prostate Cancer and Prostate-Specific Mortality: Diagnosis Is Dependent on the Intensity of Investigation
Connolly et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:271-278.
ABSTRACT | FULL TEXT  

Nine-Gene Molecular Signature Is Not Associated with Prostate Cancer Death in a Watchful Waiting Cohort
Mucci et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:249-251.
ABSTRACT | FULL TEXT  

A Switch from E-Cadherin to N-Cadherin Expression Indicates Epithelial to Mesenchymal Transition and Is of Strong and Independent Importance for the Progress of Prostate Cancer
Gravdal et al.
Clin. Cancer Res. 2007;13:7003-7011.
ABSTRACT | FULL TEXT  

A Nomogram Predicting 10-Year Life Expectancy in Candidates for Radical Prostatectomy or Radiotherapy for Prostate Cancer
Walz et al.
JCO 2007;25:3576-3581.
ABSTRACT | FULL TEXT  

Case 18-2007 -- A 54-Year-Old Man with Early-Stage Prostate Cancer
Kaufman et al.
NEJM 2007;356:2515-2520.
FULL TEXT  

Should Canadians be offered systematic prostate cancer screening?: YES
Fradet
cfp 2007;53:989-992.
FULL TEXT  

Devrait-on offrir aux Canadiens le depistage systematique du cancer de la prostate?: OUI
Fradet
cfp 2007;53:994-997.
FULL TEXT  

Prostate-Specific Antigen Levels as a Predictor of Lethal Prostate Cancer
Fall et al.
JNCI J Natl Cancer Inst 2007;99:526-532.
ABSTRACT | FULL TEXT  

Critical Review: Is Watchful Waiting a Viable Management Option for Older Men With Prostate Cancer?
Bailey and Wallace
Am J Mens Health 2007;1:18-28.
ABSTRACT  

Obesity Is Negatively Associated with Prostate-Specific Antigen in U.S. Men, 2001-2004
Werny et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:70-76.
ABSTRACT | FULL TEXT  

RESPONSE: Re: Incidence of Initial Local Therapy Among Men With Lower-Risk Prostate Cancer in the United States
Miller et al.
JNCI J Natl Cancer Inst 2006;98:1826-1826.
FULL TEXT  

Survival Associated With Treatment vs Observation of Localized Prostate Cancer in Elderly Men
Wong et al.
JAMA 2006;296:2683-2693.
ABSTRACT | FULL TEXT  

Treating Older Men With Prostate Cancer: Survival (or Selection) of the Fittest?
Litwin and Miller
JAMA 2006;296:2733-2734.
FULL TEXT  

Clinically localised prostate cancer
Wilt and Thompson
BMJ 2006;333:1102-1106.
FULL TEXT  

PSA Testing: Public Policy or Private Penchant?
Albertsen
JAMA 2006;296:2371-2373.
FULL TEXT  

Short Hairpin RNA Knockdown of the Androgen Receptor Attenuates Ligand-Independent Activation and Delays Tumor Progression
Cheng et al.
Cancer Res. 2006;66:10613-10620.
ABSTRACT | FULL TEXT  

Best practice in primary care pathology: review 4
Smellie et al.
J. Clin. Pathol. 2006;59:893-902.
ABSTRACT | FULL TEXT  

Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
Miller et al.
JNCI J Natl Cancer Inst 2006;98:1134-1141.
ABSTRACT | FULL TEXT  

Comparison of Observed and Expected Numbers of Detected Cancers in the Research Center for Cancer Prevention and Screening Program
Hamashima et al.
Jpn J Clin Oncol 2006;36:301-308.
ABSTRACT | FULL TEXT  

Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies
Mimeault and Batra
Carcinogenesis 2006;27:1-22.
ABSTRACT | FULL TEXT  

The Changing Face of Prostate Cancer
Cooperberg et al.
JCO 2005;23:8146-8151.
ABSTRACT | FULL TEXT  

Active Surveillance for Prostate Cancer: For Whom?
Klotz
JCO 2005;23:8165-8169.
ABSTRACT | FULL TEXT  

Gleason score predicted mortality rate to 20 years for untreated early prostate cancer
Barry
Evid. Based Med. 2005;10:151-151.
FULL TEXT  

Localized Prostate Cancer and DNA Ploidy
Koss
JAMA 2005;294:1207-1207.
FULL TEXT  

PSA Kinetics and Risk of Death From Prostate Cancer: In Search of the Holy Grail of Surrogate End Points
Anscher
JAMA 2005;294:493-494.
FULL TEXT  

Aggressive treatment of low grade prostate cancer is unnecessary
Mayor
BMJ 2005;330:1042-1042.
FULL TEXT  

The Natural History of Clinically Localized Prostate Cancer
Gann and Han
JAMA 2005;293:2149-2151.
FULL TEXT